People's Hospital of Shijiazhuang affiliated to Hebei Medical University - Center of Treatment of Myasthenia Gravis, Shijiazhuang, Hebei, China.
Medicine (Baltimore). 2022 Sep 30;101(39):e30867. doi: 10.1097/MD.0000000000030867.
Thymic epithelial tumors (TETs) originate in the thymic epithelial cell, including thymoma and thymic carcinoma. Surgical resection is the first choice for most patients. However, some studies have shown that the factors affecting the prognosis of these patients are not consistent. To evaluate prognostic factors in patients with surgically resected thymic epithelial tumors, we performed a meta-analysis.
We searched the Chinese biomedical literature database, Pubmed, Embase, Cochrane Library and other electronic databases. Studies including postoperative overall survival (OS) and predictors of TETs were included. We made a comprehensive analysis the hazard ratios (HRs) through a single proportional combination. HRs were combined using single proportion combinations.
The meta-analysis included 11,695 patients from 26 studies. The pooled OS was 84% at 5 years and 73% at 10 years after TETs operation. The age as continuous-year (HR 1.04, 95% confidence interval (CI) 1.02-1.04), incomplete resection (HR 4.41, 95% CI 3.32-5.85), WHO histologic classification (B2/B3 vs A/AB/B1 HR 2.76, 95% CI 1.25-6.21), Masaoka Stage (stage III/IV vs I/II HR 2.74, 95% CI 2.12-3.55,) were the poor prognostic factors.
For patients with TETs after surgical resection, advanced age, incomplete resection, WHO classification B2/B3, and higher Masaoka stage are risk factors for poor prognosis.
胸腺瘤上皮肿瘤（TETs）起源于胸腺上皮细胞，包括胸腺瘤和胸腺癌。手术切除是大多数患者的首选。然而，一些研究表明，影响这些患者预后的因素并不一致。为了评估手术切除胸腺瘤上皮肿瘤患者的预后因素，我们进行了一项荟萃分析。
我们检索了中国生物医学文献数据库、PubMed、Embase、Cochrane 图书馆和其他电子数据库。纳入了包括术后总生存率（OS）和 TETs 预测因素的研究。我们通过单一比例组合对危险比（HRs）进行了综合分析。通过单一比例组合对 HRs 进行组合。
荟萃分析纳入了 26 项研究中的 11695 名患者。TETs 手术后 5 年和 10 年的总生存率（OS）分别为 84%和 73%。年龄呈连续年（HR 1.04，95%置信区间（CI）1.02-1.04）、不完全切除（HR 4.41，95%CI 3.32-5.85）、WHO 组织学分类（B2/B3 与 A/AB/B1 HR 2.76，95%CI 1.25-6.21）、Masaoka 分期（III/IV 期与 I/II 期 HR 2.74，95%CI 2.12-3.55）是不良预后因素。
对于手术切除后的 TETs 患者，年龄较大、不完全切除、WHO 分类 B2/B3 和较高的 Masaoka 分期是预后不良的危险因素。
